ES2721172T3 - Una nueva clase de moléculas terapéuticas a base de proteínas - Google Patents
Una nueva clase de moléculas terapéuticas a base de proteínas Download PDFInfo
- Publication number
- ES2721172T3 ES2721172T3 ES17164276T ES17164276T ES2721172T3 ES 2721172 T3 ES2721172 T3 ES 2721172T3 ES 17164276 T ES17164276 T ES 17164276T ES 17164276 T ES17164276 T ES 17164276T ES 2721172 T3 ES2721172 T3 ES 2721172T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un método para preparar una composición farmacéutica, que comprende: (a) proporcionar una proteína de dominio catalítico de sialidasa que comprende un dominio catalítico de una sialidasa, en donde la proteína comprende una secuencia de dominio catalítico seleccionada entre: (i) la secuencia de aminoácidos expuesta en SEQ ID NO: 14, en donde dicha secuencia carece de los aminoácidos 1 a 273 de la secuencia de cualquiera de los aminoácidos expuesta en SEQ ID NO. 12; (ii) una secuencia de aminoácidos que comienza en el aminoácido 274 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12 y termina en el aminoácido 666 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12, y carece de los aminoácidos 1 a 273 y 667 a 901 de la secuencia de aminoácidos expuesta en SEQ ID NO. 12; (iii) una secuencia de aminoácidos que comienza en el aminoácido 274 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12 y termina en el aminoácido 681 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12, y carece de los aminoácidos 1 a 273 y 682 a 901 de la secuencia de aminoácidos expuesta en SEQ ID NO. 12; (iv) una secuencia de aminoácidos que comienza en el aminoácido 290 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12 y termina en el aminoácido 666 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12, y carece de los aminoácidos 1 a 289 y 667 a 901 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12; y (v) una secuencia de aminoácidos que comienza en el aminoácido 290 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12 y termina en el aminoácido 681 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12, y carece de los aminoácidos 1 a 289 y 682 a 901 de la secuencia de aminoácidos expuesta en SEQ ID NO: 12, en donde la proteína de dominio catalítico de sialidasa tiene actividad sialidasa; y (b) combinar la proteína de dominio catalítico de sialidasa con un vehículo o diluyente farmacéuticamente aceptable creando de este modo una composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/939,262 US7807174B2 (en) | 2002-11-22 | 2004-09-10 | Class of therapeutic protein based molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2721172T3 true ES2721172T3 (es) | 2019-07-29 |
Family
ID=36060467
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15180371.5T Expired - Lifetime ES2626845T3 (es) | 2004-09-10 | 2005-07-21 | Una nueva clase de moléculas terapéuticas a base de proteínas |
| ES05790917.8T Expired - Lifetime ES2554787T3 (es) | 2004-09-10 | 2005-07-21 | Una nueva clase de moléculas terapéuticas a base de proteínas |
| ES17164276T Expired - Lifetime ES2721172T3 (es) | 2004-09-10 | 2005-07-21 | Una nueva clase de moléculas terapéuticas a base de proteínas |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15180371.5T Expired - Lifetime ES2626845T3 (es) | 2004-09-10 | 2005-07-21 | Una nueva clase de moléculas terapéuticas a base de proteínas |
| ES05790917.8T Expired - Lifetime ES2554787T3 (es) | 2004-09-10 | 2005-07-21 | Una nueva clase de moléculas terapéuticas a base de proteínas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7807174B2 (es) |
| EP (4) | EP3018204B1 (es) |
| JP (2) | JP4764881B2 (es) |
| KR (1) | KR20070064619A (es) |
| CN (2) | CN101426906B (es) |
| AU (1) | AU2005285461B2 (es) |
| BR (1) | BRPI0515646B8 (es) |
| CA (2) | CA2823429C (es) |
| DK (3) | DK1786902T3 (es) |
| ES (3) | ES2626845T3 (es) |
| IL (3) | IL181779A (es) |
| PT (3) | PT3241898T (es) |
| RU (1) | RU2468080C2 (es) |
| TR (1) | TR201905393T4 (es) |
| WO (1) | WO2006031291A2 (es) |
| ZA (1) | ZA200702915B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210528A1 (en) * | 1999-03-05 | 2010-08-19 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
| US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| CN1729013B (zh) * | 2002-11-22 | 2012-10-03 | 耐百生物制药有限公司 | 广谱抗病毒化合物、药物制剂及其用途 |
| US8512710B2 (en) | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
| CN101002512B (zh) * | 2004-11-10 | 2013-12-04 | 日立化成株式会社 | 附有粘着辅助剂的金属箔及使用其的印刷配线板 |
| CN101553581A (zh) * | 2005-10-25 | 2009-10-07 | Mnd诊断有限公司 | 用于检测流感病毒的组合物以及使用该组合物的试剂盒和方法 |
| AU2015215955B2 (en) * | 2006-01-24 | 2016-12-01 | Ansun Biopharma, Inc. | Technology for preparation of macromolecular microspheres |
| AU2013237761B8 (en) * | 2006-01-24 | 2015-06-04 | Ansun Biopharma, Inc. | Technology for preparation of macromolecular microspheres |
| EP1981483A1 (en) * | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| US8273381B1 (en) * | 2006-04-14 | 2012-09-25 | Auburn University | Compositions for and methods of controlling olfactory responses to odorants |
| WO2008076938A1 (en) * | 2006-12-14 | 2008-06-26 | University Of Iowa Research Foundation | Method of making cyclic polypeptides with inteins |
| JP5436225B2 (ja) * | 2007-02-20 | 2014-03-05 | ディーエスエム アイピー アセッツ ビー．ブイ． | 新規シアリダーゼ |
| US8124632B2 (en) * | 2007-08-03 | 2012-02-28 | Romark Laboratories, L.C. | Alkylsulfonyl-substituted thiazolide compounds |
| EP3078377A3 (en) * | 2009-05-12 | 2017-04-05 | Romark Laboratories, L.C. | Nitazoxanide and tizoxanide as anti-viral agents |
| MX341877B (es) | 2009-06-26 | 2016-09-06 | Romark Laboratories L C * | Compuestos y métodos para tratar influenza. |
| EP2459714A1 (en) * | 2009-07-31 | 2012-06-06 | Danisco US Inc. | Proteases with modified pre-pro regions |
| JP2013510169A (ja) * | 2009-11-06 | 2013-03-21 | ネクスバイオ，インク． | 呼吸器管の治療及び予防のための方法、化合物、及び組成物 |
| CA2864746A1 (en) | 2012-02-17 | 2013-08-22 | Ansun Biopharma, Inc. | Methods, compounds and compositions for treatment of influenza and parainfluenza patients |
| US20140154308A1 (en) * | 2012-06-28 | 2014-06-05 | Ansun Biopharma, Inc. | Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture |
| JP2015527310A (ja) | 2012-06-28 | 2015-09-17 | アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. | 下気道および中枢気道への送達用微粒子製剤ならびに製造方法 |
| KR102047235B1 (ko) | 2012-12-24 | 2019-11-22 | 바이엘 헬스케어 엘엘씨 | 단작용성 인자 vii 폴리펩티드 |
| JP6471385B2 (ja) | 2013-03-15 | 2019-02-20 | グラディエーター・バイオサイエンシーズ・インコーポレイテッド | 標的化剤としてのＧｌａドメイン |
| US10351828B2 (en) * | 2013-03-15 | 2019-07-16 | Ansun Biopharma, Inc. | Method of protein purification from E. coli |
| WO2014197485A1 (en) * | 2013-06-03 | 2014-12-11 | Ansun Biopharma, Inc. | Anti-viral therapeutic for infection of the eye |
| US20160120961A1 (en) * | 2013-06-10 | 2016-05-05 | Ansun Biopharma, Inc. | Treatment of merkel cell polyomavirus infection |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| US20170119859A1 (en) | 2014-05-30 | 2017-05-04 | Ansun Biopharma, Inc. | Treatment of middle east respiratory syndrome coronavirus |
| WO2016044656A1 (en) | 2014-09-17 | 2016-03-24 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus d68 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016115616A1 (en) * | 2015-01-21 | 2016-07-28 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Inhibition of cellular proteases as treatment for influenza |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| SG10202100652VA (en) | 2015-07-21 | 2021-03-30 | Univ Jefferson | Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways |
| DK3458085T5 (da) | 2016-05-20 | 2024-09-09 | Octapharma Ag | Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik |
| ES2947312T3 (es) | 2016-07-01 | 2023-08-04 | Univ Leland Stanford Junior | Conjugados para la edición dirigida de la superficie celular |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| PL3630968T3 (pl) | 2017-05-26 | 2024-10-07 | Genovis Ab | Enzymy do analizy glikanów |
| PE20201462A1 (es) | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | Metodo de direccionamiento de exosomas |
| JP7462560B2 (ja) | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| GB201800274D0 (en) * | 2018-01-08 | 2018-02-21 | Enzymatica Ab | Novel treatments |
| GB201803197D0 (en) | 2018-02-27 | 2018-04-11 | Pneumagen Ltd | Viral treatment |
| US20220370527A1 (en) * | 2018-07-20 | 2022-11-24 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| CN109991649B (zh) * | 2019-03-26 | 2021-04-06 | 华中科技大学 | 一种制备无机闪烁体膜的方法 |
| JP7343890B2 (ja) * | 2019-04-26 | 2023-09-13 | 国立大学法人東海国立大学機構 | シアリダーゼ活性を有する酵素剤及びその利用 |
| CN110038122A (zh) * | 2019-05-23 | 2019-07-23 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗支气管炎药物中的应用 |
| CA3145200A1 (en) | 2019-07-03 | 2021-01-07 | Aillis Inc. | Pharmaceutical composition for treating influenza virus infections |
| CN111450236B (zh) * | 2020-02-25 | 2023-04-07 | 西北大学 | 一种用于阻断冠状病毒感染的制剂 |
| WO2021217053A1 (en) * | 2020-04-24 | 2021-10-28 | Rezolute, Inc. | Plasma kallikrein inhibitors for the treatment of ards and related conditions |
| WO2021252129A1 (en) * | 2020-06-10 | 2021-12-16 | The Penn State Research Foundation | Process and system to lessen human coronavirus transmission and spread |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| JP2024524875A (ja) * | 2021-06-09 | 2024-07-09 | マイクロビアル マシーンズ， インコーポレイテッド | 疾患細胞を検出するための操作された微生物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3439089A (en) | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
| ATE135403T1 (de) * | 1987-03-10 | 1996-03-15 | New England Biolabs Inc | Herstellung und reinigung eines proteins, das mit einem bindungsprotein fusioniert ist |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| US5376633A (en) | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
| US5985859A (en) * | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
| BR9506262A (pt) * | 1994-06-14 | 1997-08-12 | Gist Brocades Bv | Xilanase sequência de dna isolada e purificada vetor células hospedeira microbiana microorganismo isolado processos para a preparação de uma xilanase para a degradação de xilano para deslignificar pasta de madeira e produto obtido após o tratamento da pasta de madeira |
| US5952375A (en) * | 1995-02-27 | 1999-09-14 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
| GB9513683D0 (en) * | 1995-07-05 | 1995-09-06 | Ciba Geigy Ag | Products |
| AU5546898A (en) | 1997-01-14 | 1998-08-07 | Hopital Sainte-Justine | Human lysosomal sialidase and therapeutic uses thereof |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| US20020025320A1 (en) | 1999-08-20 | 2002-02-28 | Prosper Boyaka | Sialidases as mucosal adjuvants |
| CN1405562A (zh) * | 2002-10-24 | 2003-03-26 | 肖洪武 | 一种唾液酸酶测定试剂 |
| US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| CN1729013B (zh) | 2002-11-22 | 2012-10-03 | 耐百生物制药有限公司 | 广谱抗病毒化合物、药物制剂及其用途 |
| DE10258400A1 (de) * | 2002-12-13 | 2004-06-24 | N.V. Nutricia | Trans-Sialidasen aus Trypanosoma congolense |
| EP1981483A1 (en) | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
-
2004
- 2004-09-10 US US10/939,262 patent/US7807174B2/en not_active Expired - Lifetime
-
2005
- 2005-07-21 PT PT17164276T patent/PT3241898T/pt unknown
- 2005-07-21 JP JP2007531167A patent/JP4764881B2/ja not_active Expired - Fee Related
- 2005-07-21 AU AU2005285461A patent/AU2005285461B2/en not_active Expired
- 2005-07-21 EP EP15180371.5A patent/EP3018204B1/en not_active Expired - Lifetime
- 2005-07-21 CN CN2005800372268A patent/CN101426906B/zh not_active Expired - Lifetime
- 2005-07-21 CN CN201310239638.6A patent/CN104017787B/zh not_active Expired - Lifetime
- 2005-07-21 EP EP19153015.3A patent/EP3530734A1/en not_active Withdrawn
- 2005-07-21 DK DK05790917.8T patent/DK1786902T3/en active
- 2005-07-21 RU RU2007112502/10A patent/RU2468080C2/ru active
- 2005-07-21 DK DK15180371.5T patent/DK3018204T3/en active
- 2005-07-21 PT PT151803715T patent/PT3018204T/pt unknown
- 2005-07-21 TR TR2019/05393T patent/TR201905393T4/tr unknown
- 2005-07-21 DK DK17164276.2T patent/DK3241898T3/en active
- 2005-07-21 PT PT57909178T patent/PT1786902E/pt unknown
- 2005-07-21 ES ES15180371.5T patent/ES2626845T3/es not_active Expired - Lifetime
- 2005-07-21 KR KR1020077008112A patent/KR20070064619A/ko not_active Withdrawn
- 2005-07-21 ES ES05790917.8T patent/ES2554787T3/es not_active Expired - Lifetime
- 2005-07-21 EP EP17164276.2A patent/EP3241898B1/en not_active Expired - Lifetime
- 2005-07-21 ES ES17164276T patent/ES2721172T3/es not_active Expired - Lifetime
- 2005-07-21 WO PCT/US2005/025831 patent/WO2006031291A2/en not_active Ceased
- 2005-07-21 BR BRPI0515646A patent/BRPI0515646B8/pt active IP Right Grant
- 2005-07-21 CA CA2823429A patent/CA2823429C/en not_active Expired - Lifetime
- 2005-07-21 CA CA2578050A patent/CA2578050C/en not_active Expired - Lifetime
- 2005-07-21 EP EP05790917.8A patent/EP1786902B1/en not_active Expired - Lifetime
-
2007
- 2007-03-07 IL IL181779A patent/IL181779A/en active IP Right Grant
- 2007-04-10 ZA ZA200702915A patent/ZA200702915B/xx unknown
-
2008
- 2008-10-22 US US12/256,230 patent/US7645448B2/en not_active Expired - Lifetime
-
2010
- 2010-07-05 JP JP2010153231A patent/JP5307082B2/ja not_active Expired - Fee Related
- 2010-09-02 IL IL207957A patent/IL207957A/en active IP Right Grant
-
2015
- 2015-09-06 IL IL241227A patent/IL241227B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2533874T3 (es) | Armazón proteico | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| AR108277A2 (es) | Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas | |
| ES2619332T3 (es) | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma | |
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| CO5700784A2 (es) | Polipeptidos de virus de papiloma humano y composiciones in- munogenas | |
| ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
| ES2571879T3 (es) | Moléculas de una sola cadena de TNFSF | |
| CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
| CY1110941T1 (el) | Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας | |
| ES2531142T3 (es) | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden | |
| CY1112267T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| JP2010510315A5 (es) | ||
| DK1109831T3 (da) | Cytotoksiske peptider modificeret ved store eller lipofile dele | |
| ECSP055708A (es) | Sales bencenosulfonato de derivadosde 4-fluoro-2-cianopirrolidina | |
| DE602004001727D1 (de) | Verfahren zur herstellung cyclischer peptide | |
| BRPI0519705A2 (pt) | composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo | |
| BRPI0514411A (pt) | formulação, e, método de produzir uma formulação | |
| TR200200252T2 (tr) | Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı | |
| AR030278A1 (es) | Peptido modulador del receptor de trombopoyetina | |
| ATE495247T1 (de) | Chromoprotein und fluoroproteine |